or Try an Advanced Search...

    Technical Analysis for BEAM - Beam Therapeutics Inc.

    Grade Last Price % Change Price Change
    D 23.06 -1.58% -0.37
    BEAM closed down 1.62 percent on Monday, July 1, 2024, on 65 percent of normal volume. It ran into resistance at its 50 day moving average.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical BEAM trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.04%
    50 DMA Resistance Bearish 0.04%
    Down 3 Days in a Row Weakness 0.04%
    Fell Below 50 DMA Bearish -1.58%
    MACD Bearish Signal Line Cross Bearish -1.58%
    BB Squeeze Ended Range Expansion -1.58%
    Fell Below 20 DMA Bearish -3.84%
    Bollinger Band Squeeze Range Contraction -3.84%
    Inside Day Range Contraction -3.84%
    20 DMA Support Bullish -7.17%
    Older End-of-Day Signals for BEAM ...

       Recent Intraday Alerts

    Alert Time
    Down 2 % about 5 hours ago
    Down 1% about 6 hours ago
    60 Minute Opening Range Breakdown about 6 hours ago
    50 DMA Resistance about 9 hours ago
    10 DMA Resistance about 10 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    BEAM Chart by TradingView
    Basic chart:

    Profile

    Beam Therapeutics Inc., a biotechnology company, engages in developing precision genetic medicines for patients suffering from serious diseases in the United States. It is developing therapies for the development of sickle cell disease and beta-thalassemia; CAR-T cell therapies for pediatric T-cell acute lymphoblastic leukemia and pediatric acute myeloid leukemia; therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1A; and therapies for ocular and central nervous system disorders. The company was founded in 2017 and is based in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Gene Therapy Acute Myeloid Leukemia Central Nervous System Disorders Leukemia Nervous System Disorders Antitrypsin Deficiency Sickle Cell Disease Acute Leukemia Acute Lymphoblastic Leukemia Thalassemia Beta Thalassemia Glycogen Storage Disorder

    Is BEAM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 27 Beam Therapeutics (BEAM) Begins Dosing in Phase I/II AATD Study
    Jun 26 Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)
    Jun 14 Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
    Jun 6 Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
    May 30 Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
    May 14 Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
    May 13 15 Best ARK Stocks To Buy Now
    May 9 Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
    May 9 Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
    May 8 Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
    See more BEAM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 49.5
    52 Week Low 16.95
    Average Volume 1,399,471
    200-Day Moving Average 26.64
    50-Day Moving Average 23.64
    20-Day Moving Average 24.17
    10-Day Moving Average 23.76
    Average True Range 1.32
    RSI (14) 43.50
    ADX 9.78
    +DI 20.02
    -DI 24.25
    Chandelier Exit (Long, 3 ATRs) 23.79
    Chandelier Exit (Short, 3 ATRs) 26.15
    Upper Bollinger Bands 25.81
    Lower Bollinger Band 22.54
    Percent B (%b) 0.16
    BandWidth 13.53
    MACD Line -0.19
    MACD Signal Line -0.11
    MACD Histogram -0.0793
    Fundamentals Value
    Market Cap 1.88 Billion
    Num Shares 81.5 Million
    EPS -4.17
    Price-to-Earnings (P/E) Ratio -5.53
    Price-to-Sales 29.03
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 25.04
    Resistance 3 (R3) 25.23 24.75 24.71
    Resistance 2 (R2) 24.75 24.25 24.66 24.60
    Resistance 1 (R1) 23.90 23.93 23.67 23.71 24.49
    Pivot Point 23.43 23.43 23.31 23.33 23.43
    Support 1 (S1) 22.58 22.92 22.34 22.39 21.61
    Support 2 (S2) 22.10 22.61 22.01 21.50
    Support 3 (S3) 21.25 22.10 21.39
    Support 4 (S4) 21.06